Recall back in April, 2013 Astra-Zeneca bought a small biotech called Alphacore. Alphacore is only in Phase I trials, and years away from commercialization. Same thing could happen to ACTC. Somebody like Genentech who markets Avastin and Lucentis for wet AMD may be highly interested in ACTC. They know that we could potentially make their lucrative 2 drugs effectively obsolete in just a mere few yrs. So figure how much revenue genetech gets from their present drugs (billions) and you now have a benchmark for how much ACTC may be worth to genentech! This pricetag is not unthinkable if you tell genentech shareholders that if they fail to act, the revenue stream from avastin/lucentis will wither away anyway replaced by actc's stem cell therapy! Think about it, consider the possibilities.
big pharma must always consider their own shareholders. This early in act's trial stages would be a huge gamble at this time for any buyer. Not saying it couldn't happen, but if it did at this stage my guess 3 to 5 times current market cap. IMHO